Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Unum Therapeutics Inc. (NASDAQ: UMRX).

Full DD Report for UMRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: UMRX)

Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-20-03 at the 2018 ASH Annual Meeting
- Complete Responses Observed in Three of Six Patients at Dose Level 1 and One of Three Patients at Dose Level 2 - - No SAEs of Cytokine Release Syndrome or Neurological Events Observed in Dose Levels 1 or 2 - - Currently Dosing Patients at Dose Level 3 -    &...
Source: GlobeNewswire
Date: December, 02 2018 21:00
Unum Therapeutics Presents Preliminary Results from Ongoing Phase 1 Study ATTCK-17-01 at the 2018 ASH Annual Meeting
CAMBRIDGE, Mass., Dec. 01, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), today announced preliminary results from the ongoing Phase 1 ATTCK-17-01 study, testing ACTR087 in combination with SEA-BCMA in patients with relapsed/refractory multiple myeloma (r/r MM) at the Ameri...
Source: GlobeNewswire
Date: December, 01 2018 21:25
Unum Therapeutics to Present Preclinical Data on a New, Emerging Platform Technology for Solid Tumors at the SITC Annual Meeting
CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), today announced that the Company will present preclinical data on a new proprietary technology platform called B olt- O n Chi meric R eceptor, or BOXR, designed to improve the effectiveness of T ce...
Source: GlobeNewswire
Date: November, 06 2018 08:01
Unum Therapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on November 12, 2018 at 4:30 P.M. ET
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal Antibody-Coupled T-cell Receptor (ACTR) technology platform, today annou...
Source: GlobeNewswire
Date: November, 05 2018 07:00
Unum Therapeutics to Present Preliminary Results from Ongoing Phase 1 Studies ATTCK-20-03 and ATTCK-17-01 at the 2018 ASH Annual Meeting
CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal Antibody-Coupled T cell Receptor (ACTR) technology platform, today annou...
Source: GlobeNewswire
Date: November, 01 2018 09:01
Report: Developing Opportunities within Waste Management, Cubic, Unum Therapeutics, Highwoods Properties, Trinity Industries, and Cerner - Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Waste Management, Inc. (NYSE:WM), Cubic Corporation (NYSE:CUB), Unum Ther...
Source: GlobeNewswire
Date: November, 01 2018 07:40
Unum Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal Antibody-Coupled T cell Receptor (ACTR) technology platform, will prese...
Source: GlobeNewswire
Date: September, 07 2018 07:00
Unum Therapeutics Inc. (UMRX) CEO Chuck Wilson on Q2 2018 Results - Earnings Call Transcript
Unum Therapeutics Inc. (UMRX) Q2 2018 Results Earnings Conference Call August 13, 2018 05:00 PM ET Executives Mary Conway - Investor Relations Chuck Wilson - Chief Executive Officer Michael Vasconcelles - Chief Medical Officer Christiana Stamoulis - President and Chief Financia...
Source: SeekingAlpha
Date: August, 13 2018 20:40
Unum Therapeutics beats by $0.04, misses on revenue
Unum Therapeutics (NASDAQ: UMRX ): Q2 EPS of -$0.31 beats by $0.04 . More news on: Unum Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 13 2018 16:15
Unum Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
– IND for First Solid Tumor Program, ACTR T cells in Combination with Trastuzumab in Patients with HER2+ Advanced Cancers Now Active; Expect to Initiate Phase I Trial by End of 2018 – CAMBRIDGE, Mass., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMR...
Source: GlobeNewswire
Date: August, 13 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1411.4911.3011.7911.2586,382

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-0711,94954,87121.7765Cover
2018-12-0619,22038,89849.4113Short
2018-12-048,42622,32737.7391Short
2018-12-0310,04657,16717.5731Cover
2018-11-303,70257,7236.4134Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on UMRX.


About Unum Therapeutics Inc. (NASDAQ: UMRX)

Logo for Unum Therapeutics Inc. (NASDAQ: UMRX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: UMRX)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: August, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 13 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: April, 05 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: April, 04 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: March, 30 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: March, 30 2018
      Amendment to a previously filed Form 3
      Filing Type: 3/AFiling Source: edgar
      Filing Date: March, 29 2018
      Amendment to a previously filed Form 3
      Filing Type: 3/AFiling Source: edgar
      Filing Date: March, 29 2018

       

       


      Daily Technical Chart for (NASDAQ: UMRX)

      Daily Technical Chart for (NASDAQ: UMRX)


      Stay tuned for daily updates and more on (NASDAQ: UMRX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: UMRX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in UMRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of UMRX and does not buy, sell, or trade any shares of UMRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/